In hypertrophic cardiomyopathy (HCM) patients undergoing surgical myectomy, we sought to determine the association between pre-operative cardiac magnetic resonance (CMR) findings, small intramural coronary arteriole dysplasia (SICAD) on histopathology, and ventricular tachycardia (VT).
Multiple post-mortem studies have documented myocardial fibrosis (interstitial or replacement) in hypertrophic cardiomyopathy (HCM) patients that is distinct from the pattern observed in coronary artery disease (CAD) or patients with dilated cardiomyopathy (1, 2) . With the recent emergence of cardiac magnetic resonance (CMR), including delayed hyperenhancement magnetic resonance imaging (DHE-MRI), it is now possible to accurately detect areas of myocardial fibrosis/scarring in vivo with a high degree of sensitivity (3) (4) (5) . Areas of delayed hyperenhancement on CMR have been shown to correlate with histologically proven myocardial scar (4, 6) .
In HCM patients, scarring, detected in vivo on DHE-MRI ( Fig. 1) , has been correlated with wall thickness (7) (8) (9) , regional function (8) , and ventricular tachyarrhythmias (10 -12) . The etiology of myocardial scarring in HCM patients is debated, and multiple potential factors have been proposed, including left ventricular (LV) hypertrophy and dynamic left ventricular outflow tract (LVOT) gradient, resulting in potential pressure necrosis causing small intramural coronary arteriole dysplasia (SICAD) (1) . However, all such previous associations have been demonstrated in necropsy studies of HCM patients presenting with sudden cardiac death (SCD) (1, 2) or patients who underwent cardiac transplantation (6) , raising a concern for a selection bias in that only a high-risk population was studied. We sought to study the association between basal interventricular septal thickness, myocardial scarring (both detected by CMR), SICAD (demonstrated by histopathology), and ventricular tachyarrhythmia in HCM patients who underwent surgical myectomy.
Methods
Population. This was an observational study of 60 consecutive HCM patients with symptomatic LVOT obstruction, preserved left ventricular ejection fraction (LVEF), and no angiographic CAD who underwent comprehensive clinical, echocardiographic, CMR, and angiographic evaluation followed by surgical myectomy (generally within 30 days). These patients were subsequently entered into a registry. HCM was defined as hypertrophied and nondilated LV in absence of another cardiac or systemic disease that could result in a similar magnitude of hypertrophy (13) (14) (15) . All patients were symptomatic at the time of surgery (100% in New York Heart Association functional class III) from LVOT obstruction at baseline (resting or provokable LVOT gradient Ն50 mm Hg), despite treatment with maximally tolerated medications. Criteria for study exclusion were: ejection fraction Ͻ55%, angiographic obstructive CAD (Ͼ30% in at least 1 epicardial coronary artery), history of myocardial infarction, or the presence of pacemakers, defibrillators, or aneurysm clips precluding CMR. Pre-operative clinical, echocardiographic, CMR, and angiographic findings, along with post-operative surgical histopathology findings, were recorded from the electronic medical record. The Social Security Death Index was queried, and survival was ascertained during follow-up. This retrospective registry is approved by the local institutional review board with a waiver of individual informed consent. Echocardiography. Transthoracic echocardiography was performed using commercially available HDI 5000 (Philips Medical Systems, Bothell, Washington) and Acuson Sequoia (Siemens Medical Solution USA, Malvern, Pennsylvania) machines. Resting LVOT peak velocity was measured by continuous-wave Doppler echocardiography, and resting LVOT pressure gradient was estimated by using a simplified Bernoulli equation (16) . Care was taken to avoid contamination of the LVOT waveform by the mitral regurgitation jet (17) . In patients with resting LVOT gradients Ͻ30 mm Hg, provocative maneuvers, including Valsalva and amyl nitrite were also used to measure a provokable LVOT gradient. Maximal LVOT gradient was defined as the highest recorded LVOT gradient (resting or provokable) in a patient. Holter monitoring. The subjects had pre-operative arrhythmia monitoring performed using a 48-h Holter monitor as part of their clinical workup. Presence of ventricular tachycardia (VT) (sustained or nonsustained), defined as 3 or more consecutive ventricular beats at a rate Ͼ120 beats/min, was documented (18) . CMR. The CMR examinations were performed on 1.5 T MR scanners (Siemens Medical Solutions, Erlangen, Germany), either Sonata (40 mT/m maximum gradient strength, 200 T/m/s maximum slew rate) or Avanto (45 mT/m maximum gradient strength, 200 T/m/s maximum slew rate), using electrocardiographic gating. Scout images were acquired initially to identify the cardiac axes. Subsequently, balanced steady-state free precession images were acquired: echo time (TE) ϭ 1.6 ms, repetition time (TR) ϭ 3.3 ms, flip angle ϭ 70°, temporal resolution ϭ 68 ms, and slice thickness ϭ 6 This gave a spatial resolution of 1.5 to 2.1 mm (x-direction) by 1.1 to 1.4 mm (y-direction). LVEF and end-diastolic basal interventricular septal thickness were measured by standard off-line analysis of short-axis cine images, using Argus analytical software (Siemens Medical Solutions). The presence and amount of scar was assessed using phase-sensitive DHE-MRI ( Fig. 1) , evaluating only the anteroseptum at the basal and midventricular levels to approximately correspond with the area removed on myectomy (as illustrated in Fig. 2 ). For quantitation of scar, inner and outer myocardial edges were manually delineated. Scar was determined semiautomatically (as a percentage of total myocardium) using a viability prototype software (Siemens Medical Solutions, Erlangen, Germany) and defined as having an intensity Ͼ2 SDs above normal myocardium (identified using a user-specified region of interest) (20, 21) . Any areas that were identified as scar by the software, but not deemed to be scar by the user, were excluded manually by the user. Such quantitative scar analysis has been shown to be highly reproducible in a previous study (20) . The degree of scar was subsequently graded as follows: none, mild (1% to 25%), moderate (26% to 50%), and severe (Ͼ50%), as described in previous DHE-MRI studies (22, 23) . CMR assessment was blinded from all other analyses. Myectomy. All patients underwent surgical myectomy without coronary revascularization using techniques as previously described ( Fig. 2) (24, 25) . Histopathology. All specimens were fixed in 10% formalin and grossly examined by the cardiovascular pathology staff (E.R.R. and C.T.). Particular attention was placed in sectioning along longitudinally oriented fascicles of muscle during gross evaluation to allow for better assessment of myocyte disarray in the microscopic examination. The endocardium was always examined, and sections perpendicular to areas of thickened endocardium were taken. Formalin-fixed tissue was routinely processed for paraffin embedding. Sections were stained with hematoxylin-eosin and Movat pentachrome stains. Histologic sections were evaluated for the presence of myocyte disarray, fibrosis, and SICAD. SICAD was defined by the presence of intimal and/or medial thickening with smooth muscle proliferation and disorganization (Fig. 3) . The severity of SICAD was assessed based on the frequency that abnormal vessels were found and graded semiquantitatively as follows: absent (none to only a single affected artery), mild (1% to 25% of arteries affected), moderate (26% to 50%), and severe (Ͼ50%). This grading has been adapted at our institution, based upon previous work (1, 2) . Similarly, degree of myocardial fibrosis was assessed as normal, mild, moderate, and severe, as previously described (1). Histopathologic analysis was blinded from all other analyses. Statistics. Baseline demographics, risk factors, and clinical variables are descriptively summarized. Continuous variables are expressed as mean Ϯ SD and/or median. Categorical data are presented as percentage frequency. Differences between groups were compared with the use of the Student t test or analysis of variance (for parametric variables) and Mann-Whitney test (for nonparametric variables) for continuous variables. The chi-square test was used for categorical variables. The Pearson correlation coefficient method was utilized to test for association between continuous variables. Receiver-operator characteristic (ROC) curve analysis was performed to discriminate between patients with or without SICAD, based upon the degree of 
Results
The baseline data of the entire study population is shown in Table 1 . There have been no deaths or cardiac transplantation in the follow-up period (308 Ϯ 180 days) in this group.
Of the study group, 53 (88%) patients had Holter monitoring, of which 10 (19%) had VT. Only 2 patients had an automated implantable defibrillator placed during the follow-up period. Histopathologic data. In the study group, 15 (25%) patients had no SICAD, 33 (55%) had mild, 10 (17%) had moderate, and 2 (3%) had severe SICAD. Based upon the presence or absence of SICAD, patients were divided into 2 groups: group A: SICAD (n ϭ 45) and group B: no SICAD (n ϭ 15); and the characteristics of these groups are shown in Table 1 . Also, the classification based on fibrosis on histopathology was as follows: 19 (32%) patients with a normal pattern of fibrosis, 33 (55%) with mild, and 8 (13%) with moderate fibrosis. Imaging data versus histopathology. As demonstrated in Table 1 , the mean LVEF and LVOT gradients (both Characteristics of the Study Population Median basal interventricular septal thickness in the patient population was 1.9 cm (range 1.5 to 3.9 cm). On ROC curve analysis, basal interventricular septal thickness had a significant association with presence or absence of SICAD (area under the curve ϭ 0.76, p Ͻ 0.001, 95% CI: 0.62 to 0.88). For our population, based on ROC curve analysis, at a basal interventricular septal thickness cutoff of 1.95 cm, the sensitivity and specificity for predicting the presence of SICAD were 58% and 80%, respectively. The distribution of basal interventricular septal scarring on DHE-MRI was as follows: none (22, or 37%), mild (33, or 55%), moderate (4, or 7%), and severe (1, or 2%). On chi-square testing, there was a strong association between degree of scarring noted on DHE-MRI, and fibrosis reported on histopathology (p Ͻ 0.001), as follows. Of the 22 patients with no scar on DHE-MRI, 19 had normal fibrosis reported on histopathology. Similarly, 33 patients had evidence of mild fibrosis (on histopathology) and scar (on DHE-MRI). There was a weak correlation between basal interventricular septal thickness and scar percentage, measured on CMR (r ϭ 0.30, p ϭ 0.02). The distribution of patients, based upon presence or absence of scar on DHE-MRI is shown in Table 2 . As demonstrated in Table 2 , the mean basal interventricular septal thickness was significantly higher in patients with DHE-MRI scarring compared with those without. Also, a greater percentage of patients with scarring seen on DHE-MRI had evidence of VT on Holter monitoring (27% vs. 5%, p ϭ 0.03).
As shown in Table 1 , a greater percentage of patients with SICAD had evidence of myocardial scarring on DHE-MRI as compared with those without SICAD. Figure 4 demonstrates the significant association between different degrees of scarring, seen on DHE-MRI and SICAD. Of the 15 patients without SICAD, 12 (80%) had no scar on DHE-MRI, whereas 23 (70%) with mild SICAD had evidence of mild scar. On ROC analysis, scar percentage on DHE-MRI was a significant predictor of the presence of SICAD (area under the curve: 0.77, p ϭ 0.002, 95% CI: 0.63 to 0.92). Subsequently, we performed univariate and multivariate logistic regression analysis to test the association between myocardial scarring noted on DHE-MRI and multiple potential clinical and imaging variables. The results are shown in Table 3 . Based on the logistic regression analysis, the odds of having myocardial scarring on DHE-MRI was significantly higher in presence of SICAD (odds ratio [OR]: 14 [95% CI: 3 to 60], p ϭ 0.009), as compared to septal thickness less than the median (OR: 6 [95% CI: 2 to 19], p ϭ 0.05).
Discussion
To the best of our knowledge, this is the first in vivo study to demonstrate an independent association between pres- Figure 4 Association Between Degree of Myocardial Scarring on DHE-MRI and SICAD Association between degree of myocardial scarring on delayed hyperenhancement cardiac magnetic resonance (DHE-MRI) and small intramural coronary arteriole dysplasia (SICAD) in the study population. Values are n (%), mean Ϯ SD (range) median, mean Ϯ SD, or mean Ϯ SD (range).
Characteristics of the Study Population, Based Upon Presence or Absence of Scar on CMR
Abbreviations as in Table 1 .
ence (and degree) of SICAD by histopathology and myocardial scarring detected by DHE-MRI in a series of HCM patients. We demonstrate, using CMR, that there is a significant association between maximal basal interventricular thickness, myocardial scarring (both evaluated by CMR), and SICAD (described on histopathology) in the myectomy specimen that is removed at surgery in HCM patients who underwent surgical myectomy for symptomatic LVOT obstruction. No patient had evidence of significant epicardial CAD on pre-operative angiography, and all patients had preserved LVEF. We further demonstrate that the association between degree of SICAD and presence of DHE-MRI scarring was independent of other factors including age, sex, hypertension, LVOT gradient, and myocyte disarray. It also appears that the association of DHE-MRI scarring with SICAD is much stronger than with basal septal thickness. Previous studies have performed quantitative/semiquantitative analysis of the degree of SICAD and scar in a necropsy setting on the entire heart (2). However, in our study, only basal septal tissue removed during myectomy was available. Thus, a semiquantitative estimation of scar and SICAD (as percentage of the myocardial portion removed at myectomy) was performed. The scar assessment and quantification was performed in a semiautomatic fashion using DHE-MRI. For the purpose of this study, we specifically recorded the presence of DHE-MRI scar in the basal anteroseptum at the basal and mid-ventricular levels to approximately correspond with the area removed on myectomy (Fig. 2) . With the recent emergence of DHE-MRI, it is now possible to precisely detect areas of myocardial fibrosis/scarring in vivo with a high degree of sensitivity (3) (4) (5) . Areas of delayed hyperenhancement have been shown to correlate with histologically proven myocardial scar (4, 6) . Hence, we can have a detailed "in vivo" evaluation of myocardial scarring, which, in the past was only done in histopathologic specimens.
As demonstrated in recent studies (10 -12) , there was a significant association between scarring seen on DHE-MRI and occurrence of VT. However, longer-term follow-up data will be required to conclusively demonstrate the association between SICAD, scarring, and increased risk for sudden death (not just VT). Previous observations demonstrating the association between scarring and SICAD were derived from autopsy studies of HCM patients who died suddenly (1, 2) . These studies have the potential for a selection bias as only a high-risk sudden-death phenotype was studied.
Previous histopathologic studies have reported an increased frequency of SICAD, particularly in the interventricular septum, in HCM patients (1) . That study also suggested that besides increased intramyocardial wall tension, there are other potential factors in the pathogenesis of SICAD, including the underlying cardiomyopathy itself (1) . The observation of a strong association between SICAD and increased septal thickness suggests that these findings may occur later in the HCM disease process. Another association that needs further exploration is that between SICAD and genetics. Indeed, in the current study, significantly more patients with SICAD had a positive family history of HCM, compared to those without SICAD. Irrespective of the etiology and duration, it is well documented using CMR and positron emission tomography that HCM patients have evidence of microvascular dysfunction (26, 27) . In a CMR study of 35 HCM patients with a mean LVEF of 74 Ϯ 9%, the authors demonstrated that the resting myocardial blood flow was similar to controls; however, following vasodilator challenge, the hyperemic blood flow was substantially lower in HCM patients (27) . Thus, it is conceivable that HCM patients with SICAD have microvascular dysfunction resulting in repeated episodes of ischemia leading to myocardial scarring. Based on the current study, it appears that SICAD can be seen in HCM patients even when the basal septum is Ͻ2 cm in thickness.
Aside from ischemia, there could be other potential reasons for development of myocardial scarring in HCM. Although HCM is caused by mutation in genes encoding sarcomere components, an important component of its phenotypic expression is associated with increased myocardial connective tissue, a principal component of which is collagen (28, 29) . Different patterns of scarring have been observed (30) . There may be a generalized increase in the normal structural skeletal framework of the myocardium, or in extreme cases, individual myocytes may become encased in collagen. Myocardial scarring in HCM has been demonstrated in minimally symptomatic individuals, patients with increased frequency of ventricular arrhythmias, and individuals at high risk of sudden death or myocardial thinning and dilation (8 -12) . Clinical implications. In light of the associations demonstrated in the current study, it could be potentially important to assess whether HCM patients with SICAD (and scar) have long-term worse outcomes compared to those without. Also, in light of emerging associations between myocardial scarring and VT in HCM patients, we likely need to evaluate the continued role of beta-blockers following the surgical relief of LVOT obstruction. An interesting study would be to prospectively evaluate the impact of continued beta-blocker use on outcomes in HCM patients with significant myocardial scarring (assuming a high prevalence of coronary dysplasia) following surgical relief of LVOT obstruction. Study strengths and limitations. The study is limited by a small sample size. There is a selection bias because our patient population consisted of HCM patients deemed symptomatic due to LVOT obstruction who underwent septal myectomy. Also, only those patients who were able to undergo CMR were included in the study. However, unlike previous autopsy reports, this is a relatively lower-risk HCM population, as no patients had SCD or LV systolic dysfunction. Also, the majority of patients in the current study population had mild scarring and mild SICAD. We do not have data on stress CMR to demonstrate that these patients indeed had functionally significant microvascular dysfunction. Because of the relatively small sample size, there is potential for over-fitting in statistical analysis. The current observational study only tests associations and does not prove causality. However, scar assessment by DHE-MRI can be considered a form of in vivo histologic assessment, with the additional advantage that it can be performed in patients with any HCM phenotype with global myocardial coverage with a potential to serially monitor disease progression.
Conclusions
HCM patients with no epicardial CAD and preserved LVEF, undergoing myectomy due to symptomatic LVOT obstruction, have an increased frequency of histopathologically proven SICAD and myocardial scarring (seen on DHE-MRI) in the interventricular septum. There is a strong association between degree of SICAD and myocardial scarring, independent of age, sex, risk factors, and LVOT gradient. Although myocardial scarring is associated with VT, longer-term longitudinal studies are required to conclusively ascertain the association between scarring and sudden death.
